Washington University School of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Washington University School of Medicine sits in the top decile of US sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count).

1,502 total trials 214 currently recruiting 919 completed early-phase tilt top decile by trial count

Washington University School of Medicine: 1,502 sponsored US clinical trials, 214 recruiting.

Washington University School of Medicine sponsors 1,502 registered US clinical trials on ClinicalTrials.gov, 214 of them currently recruiting, and 919 completed. 98 of these trials are in Phase 3-4 (later-stage) and 569 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 20 trials.

Top-decile sponsor footprint

Washington University School of Medicine ranks in the top decile of sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 38/100

919 of 1,159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,502 total, page 10 of 31

COMPLETED NA

Median Nerve Stimulation Pilot

NCT04731714
COMPLETED NA

Using Health Information Technology to Improve Health Behaviors and Promote Cardiovascular Health Among Adolescent and Young Adult Cancer Survivors

NCT04623190
COMPLETED NA

Pilot Study for Postoperative Machine Learning

NCT04877535
COMPLETED Early Phase 1

Precision Functional Brain Mapping in Psilocybin

NCT04501653
TERMINATED Phase 2

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

NCT04582864
COMPLETED NA

Adapting MHealth Technology to Improve Patient Activation

NCT04893590
COMPLETED Phase 1

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

NCT04757662
COMPLETED NA

Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population

NCT04875520
COMPLETED Phase 2

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
TERMINATED NA

Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

NCT04827732
TERMINATED Phase 2

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279
COMPLETED NA

Video Education for Labor and Delivery

NCT04766099
COMPLETED NA

Cortical Network Modulation by Subthalamic Nucleus DBS

NCT04922411
COMPLETED NA

Sing for Your Saunter - Dementia Supplement

NCT04518917
COMPLETED NA

Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool

NCT04741503
COMPLETED NA

Testing Digital Technologies to Help Families Build Healthy Habits

NCT04845568
TERMINATED Phase 1

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

NCT04624113
TERMINATED NA

Continuous Glucose Monitoring Initiation at Hospital Discharge

NCT04854135
TERMINATED NA

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

NCT04508764
COMPLETED NA

Implementation of Genomics in Substance Use Disorder Treatment

NCT04768114
TERMINATED NA

The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children

NCT04678947
COMPLETED Phase 2

Smell in Covid-19 and Efficacy of Nasal Theophylline

NCT04789499
COMPLETED NA

Treatment Uptake Chatbot for Eating Disorders

NCT04806165
COMPLETED NA

Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19

NCT04718220
TERMINATED

Allosure in Simultaneous Pancreas Kidney Transplant

NCT04777617
COMPLETED Phase 1

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

NCT04542291
TERMINATED

Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

NCT04614987
COMPLETED NA

Assessing the Dose Response of a Lead Fiber Snack Prototype

NCT04729816
COMPLETED NA

Tailored Medication Management Intervention

NCT04717297
COMPLETED Phase 1

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

NCT04477512
COMPLETED Early Phase 1

NIH CCR2 AAA Study

NCT04586452
COMPLETED NA

PREVENT Tool Study: Late Effects Clinic

NCT04530825
COMPLETED NA

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

NCT04769167
COMPLETED Phase 1

Tariquidar-ondansetron Combination in Neuropathic Pain

NCT04603066
COMPLETED NA

Standardized Home Spirometry Method in Normal Population

NCT03945500
TERMINATED NA

Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers

NCT04072393
COMPLETED NA

Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell

NCT04710394
COMPLETED NA

Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism

NCT04675255
COMPLETED Phase 3

Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)

NCT04668950
TERMINATED Phase 2

Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema

NCT04679311
COMPLETED Phase 1

Leveraging Social Media to Identify and Connect Teens With Eating Disorders to a Mobile Guided Self-Help Mobile Intervention

NCT04636840
COMPLETED

Biomarkers of Trained Immunity Following MMR Vaccination

NCT04646239
TERMINATED Phase 1

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

NCT04006652
COMPLETED NA

Rural Colon Cancer Screening Toolkit Intervention

NCT04651504
COMPLETED

Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862

NCT04682769
COMPLETED Phase 3

Intravenous Thyroxine for Heart-Eligible Organ Donors

NCT04415658
COMPLETED NA

Suubi4Stigma: Addressing HIV-Associated Stigma Among Adolescents

NCT04528732
COMPLETED NA

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

NCT04565509
COMPLETED Phase 3

Ketamine to Prevent PPD After Cesarean

NCT04227704
COMPLETED NA

Safety and Feasibility of a Low Carbohydrate Diet in Children With Type 1 Diabetes

NCT04228822
← Previous Page 10 of 31 Next →

Phase Distribution

PhaseTrial count
Phase 1 332
Phase 2 237
Phase 3 40
Phase 4 58

Therapeutic Areas

Obesity 20
Breast Cancer 19
Multiple Myeloma 13
Myelodysplastic Syndromes 13
Alzheimer Disease 10
Parkinson Disease 8
Depression 8
Cancer of the Breast 7
Dementia 7
Insulin Resistance 7

What is open in the Washington University School of Medicine pipeline

214 recruiting of 1,502 indexed (14% open); 919 completed (61%).

Phase mix: 98 late (III/IV) vs 569 early (I/II) (early-phase heavy).

Top condition: Obesity (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Washington University School of Medicine: open-pipeline peers nationwide

Peers matched on 1,502 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Washington University School of MedicineYale UniversityJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,502 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Washington University School of Medicine page

1,502 registered trials is a research-attention snapshot, not an endorsement of Washington University School of Medicine or any single study.

  • 214 of Washington University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Washington University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Washington University School of Medicine pipeline card: 1,502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.